PATENT CLAIM ANALYSIS

Application Number: 15983249
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-11
Patent Classification: ["514", "007200"]

Abstract:
The present invention relates to the use of liver-selective glucokinase activators and a GLP1 analog in restoring insulin sensitivity and treating type II diabetes, including reducing body weight in subjects undergoing type II diabetes treatment.

Claim (Index 14):
The method of  claim 13 , wherein i) the complication resulting from or associated with diabetes is selected from the group consisting of nephropathy, retinopathy, neuropathy and impaired wound healing or ii) the cardiovascular disease is selected from the group consisting of arteriosclerosis and atherosclerosis.

Metadata:
- Claim Count in Document: 41.0
- Percentile: 93.0
- Lexical Diversity: 1.15625
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14071976', '12258340', '13257284', '13511771', '15142227']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7531045500551752
- 35 USC 102 Novelty (BERT): 0.5957626886082062
- Combined Prediction Score: 0.7373703639104783
- Mean Citation Score: 333.588256
- Max Citation Score: 547.05524
- Similarity Product: 418.3001738653326

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test